絞り込み

16548

広告

Management of multiple myeloma bone disease: impact of treatment on renal function.

著者 Kanellias N , Gavriatopoulou M , Terpos E , Dimopoulos MA
Expert Rev Hematol.2018 Oct 04 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (24view , 0users)

Full Text Sources

Bone disease (BD) is one of the most common features of multiple myeloma. 70-80% of patients at diagnosis present with lytic lesions which may lead to skeletal-related events. Areas covered: The aim of this review is to present the possible adverse profile of bisphosphonates (BPs) on renal function, the underlying mechanisms by which BPs may affect renal function and the novel therapeutic approaches on myeloma bone disease management. Expert Commentary: BPs remain the cornerstone in the management of myeloma-related BD. Zoledronic acid and Pamidronate are currently the gold standard, however cannot be used in patients with severe renal dysfunction. Renal impairment is another hallmark of myeloma with approximately 60% of the patients presenting with or developing renal dysfunction during the disease course. Although BPs rarely cause renal impairment, they should be administered with caution in patients with impaired renal function. The exact mechanism by which BPs cause renal impairment is yet to be elucidated. Another promising agent is denosumab, a RANKL inhibitor, which can be administrated regardless of renal function and does not need the relevant dose-adjustments.
PMID: 30285492 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード